Zealand Pharma (ZLDPF) CEO Adam Steensberg believes other drugmakers could still “win” the race in the weight-loss drug market currently dominated by Novo Nordisk (NVO) and Eli Lilly (LLY), Ian Johnston of The Financial Times reports. While Zealand Pharma has potential with its anti-obesity drugs, the products will have to compete with the popular Wegovy and Zepbound drugs developed by Novo and Eli Lilly, respectively, which are already on the market. Steensberg stressed he wanted to partner with other groups for future treatments. “We are not interested in people looking to catch up…It’s about joining forces with someone who has a strategy of how they would win in obesity,” Steensberg told the Financial Times.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on NVO:
- GLP-1 Anti-Obesity Drugs: Slim Waistlines, Fat Profits
- Novo Nordisk, Eli Lilly, others raise prices of hundreds of drugs, WSJ reports
- Novo Nordisk price target raised to DKK 800 from DKK 730 at Morgan Stanley
- Novo Nordisk upgraded to Neutral from Sell at UBS
- Analysts and Technical Indicators Agree: These 3 Stocks Are “Strong Buys” – 1/15/2024
